Crescent Biopharma (FRA:C68) Total Current Assets: €169.16 Mil (As of Mar. 2026)


FRA:C68 Crescent Biopharma Inc FRA:C68
10 GF Score
Price €14.60
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma Total Current Assets?

Crescent Biopharma FRA:C68 10 Total Current Assets is €169.16 Mil as of Mar. 2026. GuruFocus rates FRA:C68 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Crescent Biopharma's total current assets for the quarter that ended in Mar. 2026 was €169.16 Mil.

Crescent Biopharma  (FRA:C68) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Crescent Biopharma's Liquidation Value for the quarter that ended in Mar. 2026 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=163.626-13.22+0.75 * 0+0.5 * 0
=150.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Total Current Assets Related Terms

Crescent Biopharma Total Current Assets Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Total Current Assets Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Total Current Assets
33.24 202.10

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Assets Get a 7-Day Free Trial 0.00 133.72 114.65 202.10 169.16
FRA:C68
10GF Score
Crescent Biopharma Inc FRA:C68
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Crescent Biopharma's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=182.066+15.372+0+4.665
=202.10

Crescent Biopharma's Total Current Assets for the quarter that ended in Mar. 2026 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=163.626+0+0+5.536
=169.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of €169.16 Mil mean?
Crescent Biopharma (FRA:C68) has a Total Current Assets of €169.16 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Crescent Biopharma and its competitors.
Is Crescent Biopharma's Total Current Assets too high?
Crescent Biopharma's current Total Current Assets is €169.16 Mil. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Total Current Assets compare to KYTX and ZURA?
Crescent Biopharma's Total Current Assets of €169.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Crescent Biopharma and its competitors. Crescent Biopharma's current Total Current Assets is €169.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current Total Current Assets of €169.16 Mil. The current Total Current Assets is €169.16 Mil. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current Total Current Assets is €169.16 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges CBIO:USA
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score

Get the complete analysis for FRA:C68

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.60
Price